Jazz Pharmaceuticals plc — Director's Dealing 2017

Mar 1, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2017-02-27

Reporting Person: Smith Karen L. (Global Head of R&D and CMO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-02-27	Ordinary Shares	F	571	$136.97	Disposed	13668	Direct

Footnotes

F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

F2: Includes 57 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2016.